Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cycline prophylaxis to prevent cetuximab-related skin toxicity with intensified FOLFIRI in metastatic colorectal cancer
2010-019140-39Phase 3Completed
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab and FOLFIRI in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Institut Cancérologique de l'Ouest. Started Jul 2010; status: completed.
02
Drugs
cetuximabFOLFIRI
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2010-019140-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019140-39.